Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects

Blood Purification

Volumn 27, Issue 2, 2009, Pages 194-198

  Caimi, G ^a   Carollo, C ^a   Montana, M ^a   Iatrino, R ^a   Bondi B ^a   Lo Presti, R ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Elastase; Hemodialysis; Myeloperoxidase; Nitric oxide; Oxidative status

Indexed keywords

ELASTASE; MYELOPEROXIDASE; NITRIC OXIDE; POLYUNSATURATED FATTY ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID OXIDATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

AGED; ANTIOXIDANTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTE ELASTASE; LEUKOCYTES; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; PEROXIDASE; RENAL DIALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 58249098859     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000193218     Document Type: Article

References (46)

1. Culleton BF, Hemmelgarn BR: Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial 2003;16:95-100.
2. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellstrom B, Heimburger O, Lindholm B, Alvestrand A: Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2006;1:281-287.
3. Eleftheriadis T, Kartsios C, Yannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D: Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif 2008;26:317-321.
4. Haag-Weber M, Horl WH: Dysfunction of polymorphonuclear leucocytes in uremia. Semin Nephrol 1996;16:192-201.
5. Haag-Weber M, Horl WH: Uremia and infections: mechanisms of impaired cellular host defense. Nephron 1993:63:125-131.
6. Dollery CM, Owen CA, Sukhova GK, Krettek A, Shapiro SD, Libby P: Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003;107:2829-2836.
7. Hayama T, Matsuyama M, Funao K, Tanaka T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T: Benefical effect of neutrophil elastase inhibitor on renal warm ischemia-reperfusion injury in the rat. Transplant Proc 2006;38:2201-2202.
8. Maruyama Y, Lindholm B, Stenvinkel P: Inflammation and oxidative stress in ESRD: the role of myeloperoxidase. J Nephrol 2004;17(S8):72-76.
9. Kraśniak A, Drozdz M, Pasowicz M, Chmiel G, Michałek M, Szumilak D, Podolec P, Klimeczek P, Konieczyńska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W: Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007;22:515-521.
10. Morena M, Delbosc S, Dupuy, Canaud B, Cristol JP: Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005;9:37-46.
11. Galle J, Seibold S, Wanner C: Inflammation in uraemic patients: what is the link? Kidney Blood Press Res 2003;26:65-75.
12. Stenvinkel P: Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006;11:36-41.
13. Zachara BA, Gromadzinska J, Wasowic W, Zbrog Z: Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006;53:663-677.
14. Toborek M, Wasik T, Drozdz M, Klin M, Magner-Wrobel K, Kopieczna-Grzebieniak E: Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992;41:1229-1232.
15. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. QJM 1994;87:679-683.
16. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E and iron status. Free Radic Biol Med 1994;16:339-346.
17. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS: Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995;41:1135-1138.
18. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S: Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999;34:438-444.
19. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S: Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999;56:1078-1083.
20. Sandhu JS Narang APS, Bhatia KL, Adlakha J, Khullar D: Trace elements and oxidative stress in chronic renal failure. Trace Elem Electrolyt 2005;22:233-235.
21. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thèvenin M: Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-340.
22. Koken T, Serteser M, Kahraman A, Gokce C, Demir S: Changes in serum markers of oxidative stress with varying periods of haemodialysis. Nephrology 2004;9:77-82.
23. Pawlak K, Pawlak D, Mysliwiec M: Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 2005;38:700-705.
24. Valentini J, Grotto D, Paniz C, Roehrs M, Burg G, Garcia SC: The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 2008;62:378-382.
25. Heidland A, Horl WH, Heller N, Heine H, Neumann S, Heidbreder E: Release of granulocyte neutral proteinases in patients with acute and chronic renal failure. Adv Exp Med Biol 1984;167:417-431.
26. Knudsen F, Nielsen AH, Pedersen JO, Jersild C: On the kinetics of complement activation, leucopenia and granulocyte-elastase release induced by haemodialysis. Scand J Clin Lab Invest 1985;45:759-766.
27. Horl WH, Riegel W, Schollmeyer P, Rautenberg W, Neumann S: Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers. Clin Nephrol 1986;25:304-307.
28. Iijima S, Otsuka F, Takita T, Kikuchi Y: Leukopenia and rheological anomalies in leukocytes during hemodialysis in patients with chronic renal failure. Nephron 1996;74:561-566.
29. Di Massimo C, Scarpelli P, Di Lorenzo N, Caimi G, Di Orio F, Tozzi-Ciancarelli MG: Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 2006;78:1163-1167.
30. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-412.
31. Hon WM, Lee JC, Lee KH: Effect of hemodialysis on plasma nitric oxide levels. Artif Organs 2000;24:387-390.
32. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD: The role of complement in biomaterial-induced inflammation. Molec Immunol 2007;44:82-94.
33. Ono K, Ueki K, Inose K, Tsuchida A, Yano S, Nojima Y: Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Res Commun Mol Pathol Pharmacol 2000;108:341-349.
34. Wang T, Zhang X, Li JJ: The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol 2002;2:1509-1520.
35. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, Descamps-Latscha B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003;64:82-91.
36. Nakayama M, Nakayama K, Zhu WJ, Shirota Y, Terawaki H, Sato T, Kohno M, Ito S: Polymorphonuclear leukocyte injury by methylglyoxal and hydrogen peroxide: a possible pathological role for enhanced oxidative stress in chronic kidney disease. Nephrol Dial Transplant 2008;23:3096-3102.
37. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
38. Himmelfarb J, Phinney S, Izikler TA, Kane J, McMonagle E, Miller G: Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007;17:296-304.
39. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H: Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif 2008;26:371-378.
40. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G: Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008;41:381-386.
41. Morena M, Martin-Mateo M, Cristol JP, Canaud B: Rationale for antioxidant supplementation in hemodialysis patients. Saudi J Kidney Dis Transplant 2001;12:312-324.
42. Cruz DN, de Cal M, Ronco C: Oxidative stress and anemia in chronic hemodialysis: the promise of bioreactive membranes. Contrib Nephrol. Basel, Karger, 2008, vol 161, pp 89-98.
43. Cruz DN, De Cal M, Garzotto F, Brendolan A, Nalesso D, Corradi V, Ronco C: Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 2008;31:545-552.
44. Morena M, Gausson V, Mothu N, Bouchet JL, Chanas M, Grandvuillemin M, Robert A, Vela C, Canaud B, Cristol JP, Olmer M: Regional variations of low-density lipoprotein oxidizability in hemodialysis patients may explain discrepancies in interventional therapy on oxidative profile. Blood Purif 2008;26:300-310.
45. Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD: Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. Blood Purif 2008;26:213-220.
46. Briggs JD: Cause of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-1549.